Navigation Links
deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference

REYKJAVIK, Iceland, Feb. 7 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it will host a live webcast of deCODE Chief Scientific Officer Jeffrey Gulcher's presentation at Biotechnology Industry Organization (BIO) CEO and Investor Conference.

The presentation will be delivered at 2:45 PM ET / 19:45GMT on Monday, February 11 at the Waldorf-Astoria hotel in New York. The webcast can be accessed through the Investors page on deCODE's website,, and those interested in listening should log on a few minutes in advance in order to download any software or complete any sign-in that may be required. The webcast will be archived for at least one week.

About deCODE

deCODE genetics (Nasdaq: DCGN) is a global leader in applying human genetics to develop drugs and diagnostics for common diseases. Our population approach has enabled us to discover and target key biological pathways involved in conditions ranging from heart attack to cancer. We are turning these discoveries into new medicine to better treat and prevent many of the biggest challenges to public health. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at


deCODE genetics

Kristin H. Barkardottir


SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
2. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
3. deCODE Launches deCODEme(TM)
4. deCODE genetics Announces Third Quarter 2007 Financial Results
5. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
6. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
7. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
8. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
9. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
Post Your Comments:
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):